AUC values for CXCL12 levels did not discriminate between SMA (AUC: 0.520 ± 0.098; 95% CI: 0.41 to 0.63, p = 0.84), AD (AUC: 0.654 ± 0.085; 95% CI: 0.548 to 0.75, p = 0.06), FTD (AUC: 0.572 ± 0.0532; 95% CI: 0.475 to 0.665, p = 0.17), and control cases, in contrast with MS (AUC: 0.858 ± 0.057; 95% CI: 0.775 to 0.919, p = 0.000) (Figure 6C). Here, CXCL12 is linked to myeloid sarcoma.